Kyverna Therapeutics, Inc.
KYTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company carries a $518.0M market cap, placing it firmly in the small-cap category. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Market Cap
$518.0M
Beta
2.06
P/E (TTM)
—
P/E (Fwd)
-2.88
EPS (TTM)
$-3.27
EPS (Fwd)
$-2.95
ROE
-74.6%
ROA
-39.6%
Cash
$236.4M
Total Debt
$33.8M
Free CF
-$93.8M
52W Change
221.5%
Annual Financials
Cash vs Debt
Kyverna Therapeutics, Inc. holds $236.4M in cash against $33.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$93.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -74.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $5.7M (2021) to $0 (2025), a 100% decline worth watching.
With a beta above 1.5, KYTX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, KYTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kyverna Therapeutics, Inc.'s trajectory.